LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Does your unwell patient have haemophagocytic lymphohistiocytosis?

    Holloway, Amelia / Ahmed, Saad / Manson, Jessica J

    British journal of hospital medicine (London, England : 2005)

    2024  Volume 85, Issue 3, Page(s) 1–12

    Abstract: Haemophagocytic lymphohistiocytosis is a severe systemic hyperinflammatory syndrome characterised by dysregulation of immune cells and excessive production of cytokines, also known as a cytokine storm. It has distinctive clinical features with fever, ... ...

    Abstract Haemophagocytic lymphohistiocytosis is a severe systemic hyperinflammatory syndrome characterised by dysregulation of immune cells and excessive production of cytokines, also known as a cytokine storm. It has distinctive clinical features with fever, hyperferritinaemia and falling blood counts. In adults, this usually occurs secondary to an underlying driver or trigger including infection, malignancy or rheumatic diseases. Prompt treatment with immunomodulatory therapy, including corticosteroids and the recombinant IL-1 receptor antagonist anakinra, is recommended to switch off the cytokine storm. Etoposide-based regimens are sometimes needed, and newer therapies such as emapalumab and JAK inhibitors are increasingly being used. The incidence of haemophagocytic lymphohistiocytosis has increased significantly over the last 20 years which may partly reflect increased awareness of the condition. Although relatively rare, haemophagocytic lymphohistiocytosis can be encountered by a broad range of hospital physicians, so knowing how to diagnose and treat this condition is essential. This article reviews the pathogenesis, clinical features, causes, diagnosis and treatment of haemophagocytic lymphohistiocytosis to improve physician recognition and management of this condition to improve future patient outcomes.
    MeSH term(s) Adult ; Humans ; Lymphohistiocytosis, Hemophagocytic/diagnosis ; Lymphohistiocytosis, Hemophagocytic/drug therapy ; Lymphohistiocytosis, Hemophagocytic/etiology ; Cytokine Release Syndrome ; Neoplasms/complications ; Adrenal Cortex Hormones ; Diagnosis, Differential
    Chemical Substances Adrenal Cortex Hormones
    Language English
    Publishing date 2024-03-12
    Publishing country England
    Document type Journal Article ; Review
    ISSN 1750-8460
    ISSN 1750-8460
    DOI 10.12968/hmed.2023.0394
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England.

    Quick, Vanessa / Abusalameh, Mahdi / Ahmed, Sajeel / Alkoky, Hoda / Bukhari, Marwan / Carter, Stuart / Coath, Fiona L / Davidson, Brian / Doddamani, Parveen / Dubey, Shirish / Ducker, Georgina / Griffiths, Bridget / Gullick, Nicola / Heaney, Jonathan / Holloway, Amelia / Htut, Ei Ei Phyu / Hughes, Mark / Irvine, Hannah / Kinder, Alison /
    Kurshid, Asim / Lim, Joyce / Ludwig, Dalia R / Malik, Mariam / Mercer, Louise / Mulhearn, Ben / Nair, Jagdish R / Patel, Rikesh / Robson, Joanna / Saha, Pratyasha / Tansley, Sarah / Mackie, Sarah L

    Rheumatology (Oxford, England)

    2023  

    Abstract: Objectives: The National Health Service in England funds 12 months of weekly subcutaneous tocilizumab (qwTCZ) for patients with relapsing or refractory giant cell arteritis (GCA). During the COVID-19 pandemic, some patients were allowed longer treatment. ...

    Abstract Objectives: The National Health Service in England funds 12 months of weekly subcutaneous tocilizumab (qwTCZ) for patients with relapsing or refractory giant cell arteritis (GCA). During the COVID-19 pandemic, some patients were allowed longer treatment. We sought to describe what happened to patients after cessation of qwTCZ.
    Methods: Multicentre service evaluation of relapse after stopping qwTCZ for GCA. The log-rank test was used to identify significant differences in time to relapse.
    Results: 336 GCA patients were analysed from 40 centres, treated with qwTCZ for a median (interquartile range, IQR) of 12 (12-17) months. At time of stopping qwTCZ, median (IQR) prednisolone dose was 2 (0-5) mg/day. By 6, 12 and 24 months after stopping qwTCZ, 21.4%, 35.4% and 48.6% respectively had relapsed, requiring an increase in prednisolone dose to a median (IQR) of 20 (10-40) mg/day. 33.6% of relapsers had a major relapse as defined by EULAR. Time to relapse was shorter in those that had previously also relapsed during qwTCZ treatment (P = 0.0017); in those not in remission at qwTCZ cessation (P = 0.0036); and in those with large vessel involvement on imaging (P = 0.0296). Age ≥65, gender, GCA-related sight loss, qwTCZ treatment duration, TCZ taper, prednisolone dosing, and conventional synthetic DMARD use were not associated with time to relapse.
    Conclusion: Up to half our patients with GCA relapsed after stopping qwTCZ, often requiring a substantial increase in prednisolone dose. One third of relapsers had a major relapse. Extended use of TCZ or repeat treatment for relapse should be considered for these patients.
    Language English
    Publishing date 2023-11-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/kead604
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Correction to: COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort.

    Jewell, Paul D / Bramham, Kate / Galloway, James / Post, Frank / Norton, Sam / Teo, James / Fisher, Richard / Saha, Rohit / Hutchings, Sam / Hopkins, Phil / Smith, Priscilla / Joslin, Jennifer / Jayawardene, Satish / Mackie, Sarah / Mudhaffer, Ali / Holloway, Amelia / Kibble, Henry / Akter, Mosammat / Zuckerman, Benjamin /
    Palmer, Kieran / Murphy, Ciara / Iatropoulou, Domniki / Sharpe, Claire C / Lioudaki, Eirini

    BMC nephrology

    2021  Volume 22, Issue 1, Page(s) 403

    Language English
    Publishing date 2021-12-06
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2041348-8
    ISSN 1471-2369 ; 1471-2369
    ISSN (online) 1471-2369
    ISSN 1471-2369
    DOI 10.1186/s12882-021-02617-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort.

    Jewell, Paul D / Bramham, Kate / Galloway, James / Post, Frank / Norton, Sam / Teo, James / Fisher, Richard / Saha, Rohit / Hutchings, Sam / Hopkins, Phil / Smith, Priscilla / Joslin, Jennifer / Jayawardene, Satish / Mackie, Sarah / Mudhaffer, Ali / Holloway, Amelia / Kibble, Henry / Akter, Mosammat / Zuckerman, Benjamin /
    Palmer, Kieran / Murphy, Ciara / Iatropoulou, Domniki / Sharpe, Claire C / Lioudaki, Eirini

    BMC nephrology

    2021  Volume 22, Issue 1, Page(s) 359

    Abstract: Background: Acute kidney injury (AKI) is common among patients hospitalised with COVID-19 and associated with worse prognosis. The aim of this study was to investigate the epidemiology, risk factors and outcomes of AKI in patients with COVID-19 in a ... ...

    Abstract Background: Acute kidney injury (AKI) is common among patients hospitalised with COVID-19 and associated with worse prognosis. The aim of this study was to investigate the epidemiology, risk factors and outcomes of AKI in patients with COVID-19 in a large UK tertiary centre.
    Methods: We analysed data of consecutive adults admitted with a laboratory-confirmed diagnosis of COVID-19 across two sites of a hospital in London, UK, from 1st January to 13th May 2020.
    Results: Of the 1248 inpatients included, 487 (39%) experienced AKI (51% stage 1, 13% stage 2, and 36% stage 3). The weekly AKI incidence rate gradually increased to peak at week 5 (3.12 cases/100 patient-days), before reducing to its nadir (0.83 cases/100 patient-days) at the end the study period (week 10). Among AKI survivors, 84.0% had recovered renal function to pre-admission levels before discharge and none required on-going renal replacement therapy (RRT). Pre-existing renal impairment [odds ratio (OR) 3.05, 95%CI 2.24-4,18; p <  0.0001], and inpatient diuretic use (OR 1.79, 95%CI 1.27-2.53; p <  0.005) were independently associated with a higher risk for AKI. AKI was a strong predictor of 30-day mortality with an increasing risk across AKI stages [adjusted hazard ratio (HR) 1.59 (95%CI 1.19-2.13) for stage 1; p < 0.005, 2.71(95%CI 1.82-4.05); p < 0.001for stage 2 and 2.99 (95%CI 2.17-4.11); p < 0.001for stage 3]. One third of AKI3 survivors (30.7%), had newly established renal impairment at 3 to 6 months.
    Conclusions: This large UK cohort demonstrated a high AKI incidence and was associated with increased mortality even at stage 1. Inpatient diuretic use was linked to a higher AKI risk. One third of survivors with AKI3 exhibited newly established renal impairment already at 3-6 months.
    MeSH term(s) Acute Kidney Injury/diagnosis ; Acute Kidney Injury/etiology ; Acute Kidney Injury/mortality ; Acute Kidney Injury/therapy ; COVID-19/complications ; COVID-19/diagnosis ; COVID-19/epidemiology ; Cohort Studies ; Hospital Mortality ; Humans ; Incidence ; Intensive Care Units/statistics & numerical data ; Kidney Function Tests/methods ; Male ; Middle Aged ; Outcome and Process Assessment, Health Care ; Patient Acuity ; Renal Replacement Therapy/methods ; Renal Replacement Therapy/statistics & numerical data ; Risk Factors ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; United Kingdom/epidemiology
    Language English
    Publishing date 2021-11-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041348-8
    ISSN 1471-2369 ; 1471-2369
    ISSN (online) 1471-2369
    ISSN 1471-2369
    DOI 10.1186/s12882-021-02557-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top